Recent Approvals in Vaccination Against SARS-CoV-2 and the Omicron Subvariants : Episode 6

Defining SARS-CoV-2 Bivalent Vaccines and Optimizing Protection Through Vaccination

November 16, 2022

By Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; and Ryan P. McNamara, PhD
Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Video

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Jacinda Abdul-Mutakabbir, PharmD; and Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; review what encompasses a bivalent vaccine and give their perspective on how to communicate the role of the vaccine in optimizing protection for patients.

EP: 1.Overview of SARS-CoV-2 Virus and Subvariants

EP: 2.Defining Variants of Interest vs Variants of Concern

EP: 3.Impact of SARS-CoV-2 Subvariants on Vaccination

EP: 4.COVID-19 Booster Vaccination Protection Rates

EP: 5.Evolution of SARS-CoV-2 Variants on Booster Shot Development and Formulations

EP: 6.Defining SARS-CoV-2 Bivalent Vaccines and Optimizing Protection Through Vaccination

EP: 7.CDC and FDA Recommendations for SARS-CoV-2 Booster Shots

EP: 8.Influenza Vaccination With SARS-CoV-2 mRNA Booster Shots

Recent Videos

A panel of 5 experts on C. difficile infections

A panel of 5 experts on C. difficile infections

A panel of 5 experts on C. difficile infections

A panel of 5 experts on C. difficile infections

A panel of 5 experts on C. difficile infections

A panel of 5 experts on C. difficile infections

A panel of 5 experts on C. difficile infections

A panel of 5 experts on C. difficile infections

Contagion, Fall 2024 Digital Edition

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.